Related Experiment Videos
Desferoxamine blocks IL 2 receptor expression on human T lymphocytes
Journal of Immunology (Baltimore, Md. : 1950)
|April 1, 1986
Summary
The iron-chelator desferrioxamine (DF) inhibits T cell proliferation by blocking interleukin-2 (IL-2) receptor expression. This impacts early cell activation, preventing cell cycle progression in human lymphocytes stimulated by PHA.
Area of Science:
- Immunology
- Cell Biology
- Pharmacology
Background:
- T cell proliferation is crucial for adaptive immunity.
- Interleukin-2 (IL-2) and its receptor (IL-2R) are key regulators of T cell activation.
- Iron chelators, like desferrioxamine (DF), can modulate immune cell function.
Purpose of the Study:
- To investigate the mechanism by which desferrioxamine (DF) inhibits T cell proliferation.
- To determine if DF affects early T cell activation events, including IL-2 receptor expression and cell cycle progression.
Main Methods:
- Human peripheral blood mononuclear cells (MNC) were stimulated with phytohemagglutinin (PHA) in the presence or absence of DF.
- Expression of IL-2 receptor (Tac antigen), 4F2, and Ia antigens was assessed.
- IL-2 production was measured.
- Cell cycle progression was analyzed using flow cytometry.
Main Results:
- Desferrioxamine (DF) significantly reduced thymidine uptake, indicating decreased T cell proliferation.
- DF inhibited Tac antigen (IL-2 receptor) expression on PHA-stimulated MNC.
- DF did not impair the expression of 4F2 and Ia antigens or IL-2 production.
- Early DF addition blocked G0 to G1 cell cycle transition, while later addition arrested cell cycle progression.
Conclusions:
- Desferrioxamine (DF) interferes with IL-2 receptor expression, contributing to the inhibition of mitogen-induced T cell proliferation.
- DF's effects on T cell activation are linked to impaired IL-2 receptor signaling.
- Understanding DF's impact on T cell activation provides insights into immunomodulation by iron chelators.